Molecular Partners updates Radio-DARPin programs, reports strong cash position; positive.

From GlobeNewswire: 2025-01-12 13:00:00

Molecular Partners has announced updates on its Radio-DARPin programs, including the entry of Radio-DARPin MP0712 targeting DLL3 into a first-in-human study in 2025. Mesothelin has been named as the second target in the Radio-DARPin pipeline, with a program co-developed with Orano Med. Clinical data for MP0533 show improved response rates in cohort 8, with plans for additional dose densification in cohort 9. The Switch-DARPin platform has demonstrated conditional T cell activation and CD2 co-stimulation in solid tumors. Further updates on these programs are expected in 2025.

The company reported cash and cash equivalents of CHF 149 million as of December 31, 2024, and will provide full financial results on March 6, 2025. The IND application for MP0712 is in preparation, with plans for submission in H1 2025. The second Radio-DARPin program targets MSLN and is being co-developed with Orano Med. Molecular Partners continues to evaluate additional targets for Radio-DARPin Therapy programs in partnership with Novartis.

MP0533, a novel T cell engager, is being evaluated in a Phase 1/2a clinical trial for relapsed/refractory AML. Encouraging results have been observed in cohort 8 with increased rates and depth of responses. The Switch-DARPin platform has shown promising preclinical results in solid tumors, with plans to present further data at the AACR Annual Meeting in Q2 2025. Comprehensive biomarker analyses of the CD40 agonist MP0317 in solid tumors were presented at SITC in November 2024. Discussions are ongoing for potential combination trials of MP0317 in 2025.



Read more at GlobeNewswire: Molecular Partners Outlines Clinical Expansion Plans and